eCommons@AKU
Department of Paediatrics and Child Health

Division of Woman and Child Health

6-1-2021

Clinical, neuroimaging, and molecular spectrum of
TECPR2-associated hereditary sensory and autonomic
neuropathy with intellectual disability
Sonja Neuser
University of Leipzig Medical Center, Leipzig, Germany

Barbara Brechmann
Harvard Medical School, Boston, Massachusetts, USA.

Gali Heimer
Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Israel

Ines Brösse
Heidelberg University Hospital, Heidelberg, Germany

Susanna Schubert
University of Leipzig Medical Center, Leipzig, Germany

See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Developmental Neuroscience Commons, Pediatrics Commons, and the Women's Health
Commons

Recommended Citation
Neuser, S., Brechmann, B., Heimer, G., Brösse, I., Schubert, S., O'Grady, L., Zech, M., Srivastava, S., Ibrahim,
S., Khan, F. (2021). Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary
sensory and autonomic neuropathy with intellectual disability. Human Mutation, 42(6), 762-776.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/1013

Authors
Sonja Neuser, Barbara Brechmann, Gali Heimer, Ines Brösse, Susanna Schubert, Lauren O'Grady, Michael
Zech, Siddharth Srivastava, Shahnaz Ibrahim, and Fatima Khan

This article is available at eCommons@AKU: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr/1013

Received: 19 October 2020

|

Revised: 18 March 2021

|

Accepted: 8 April 2021

DOI: 10.1002/humu.24206

RESEARCH ARTICLE

Clinical, neuroimaging, and molecular spectrum of
TECPR2‐associated hereditary sensory and autonomic
neuropathy with intellectual disability
Sonja Neuser1
| Barbara Brechmann2,3
| Gali Heimer4,5
Susanna Schubert1 | Lauren O'Grady6 | Michael Zech7,8 |
Siddharth Srivastava2 | David A. Sweetser6
Volker Mall9,11 | Juliane Winkelmann7,8,12,13
14

| Ines Brösse3

| Yasemin Dincer9,10 |
| Christian Behrends13

15

|

|

16

| Robert J. Graham
| Parul Jayakar
| Barry Byrne17
Basil T. Darras
Bat El Bar‐Aluma4,5 | Yael Haberman4,5,18 | Amir Szeinberg4,5 |

|

Hesham M. Aldhalaan19 | Mais Hashem19 | Amal Al Tenaiji20 | Omar Ismayl20 |
Asma E. Al Nuaimi20 | Karima Maher20 | Shahnaz Ibrahim21 | Fatima Khan21 |
Henry Houlden22 | Vijayalakshmi S. Ramakumaran23 | Alistair T. Pagnamenta24
| James R. Lupski25,26,27,28
| Wen‐Hann Tan29
|
Jennifer E. Posey25

|

| Tatiana Muñoz31 |
Gehad ElGhazali20 | Isabella Herman25,27,30
| Angelika Seitz32 | Mandy Krumbiegel33 |
Gabriela M. Repetto31
| Usha Kini23
Maria Cecilia Poli26,31
| Reza Maroofian22
Jens Meiler34,35
1

| Bernt Popp
Rami Abou Jamra
Darius Ebrahimi‐Fakhari2

1

| Stephanie Efthymiou22
| Fowzan S. Alkuraya19,36
| Bruria Ben‐Zeev

4,5

|
|

|

1

Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany

2

Department of Neurology, The F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

3

Department of Pediatrics, Hospital for Children and Adolescents, Heidelberg University Hospital, Heidelberg, Germany

4

Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel

5

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

6

Department of Pediatrics, Division of Medical Genetics and Metabolism, Massachusetts General Hospital, Boston, Massachusetts, USA

7

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany

8

Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

9

Lehrstuhl für Sozialpädiatrie, Department of Pediatrics, Technische Universität München, Germany

10

Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ), Martinsried, Germany

11

kbo‐Kinderzentrum München, Munich, Germany

12

Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany

Sonja Neuser, Barbara Brechmann, Gali Heimer, Bernt Popp, Bruria Ben‐Zeev and Darius Ebrahimi‐Fakhari are equally contributed to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Human Mutation published by Wiley Periodicals LLC
762

|

wileyonlinelibrary.com/journal/humu

Human Mutation. 2021;42:762–776.

NEUSER

|

ET AL.

763

13

Munich Cluster for Systems Neurology (Synergy), Ludwig‐Maximilians‐Universität München, Munich, Germany

14

Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

15

Department of Anesthesia, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

16

Nicklaus Children's Hospital, Miami, Florida, USA

17

Powell Gene Therapy Center, University of Florida, Gainesville, Florida, USA

18

Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

19

Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

20

Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

21

Department of Paediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan

22

Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK

23

Oxford Centre for Genomic Medicine, Oxford, UK

24

NIHR Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

25

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

26

Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

27

Texas Children's Hospital, Houston, Texas, USA

28

Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA

29

Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA

30

Department of Pediatrics, Section of Pediatric Neurology and Developmental Neuroscience, Baylor College of Medicine, Houston, Texas, USA

31

Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile

32

Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany

33

Institute of Human Genetics, Friedrich‐Alexander‐Universität (FAU), Erlangen, Germany

34

Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA

35

Institute for Drug Discovery, University of Leipzig Medical Center, Leipzig, Germany

36

Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Correspondence
Sonja Neuser, Institute of Human Genetics,
University of Leipzig Medical Center,
Philipp‐Rosenthal‐Straße 55, 04103 Leipzig,
Germany.
Email: sonja.neuser@medizin.uni-leipzig.de and
s.neuser.md@gmail.com

Abstract
Bi‐allelic TECPR2 variants have been associated with a complex syndrome with
features of both a neurodevelopmental and neurodegenerative disorder. Here, we
provide a comprehensive clinical description and variant interpretation framework
for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi‐allelic TECPR2‐variants. We systemically reviewed
clinical and molecular data from this cohort and 11 cases previously reported.
Phenotypes were standardized using Human Phenotype Ontology terms. A cross‐
sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal
hypopnea as core manifestations. A review of brain magnetic resonance imaging
scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N‐ and
C‐terminal regions containing β‐propeller repeats. Despite constituting nearly half
of disease‐associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish
Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/
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treatment of individuals with TECPR2‐associated disorder. This sets the stage for
future prospective natural history studies.
KEYWORDS

Human Phenotype Ontology, neurodevelopmental disorder, sensory autonomic neuropathy,
spastic paraplegia, TECPR2

1

| INTRODUCTION

known/novel disease‐associated TECPR2‐variants. Based on a detailed review of the published cases and comparison with the herein

TECPR2 belongs to the tectonin β‐propeller repeat‐containing protein

described individuals, we provide a systematic quantitative clinical

family and is implicated in the autophagy pathway (Oz‐Levi et al., 2013;

synopsis based on Human Phenotype Ontology (HPO) (Köhler

Stadel et al., 2015). Autophagy is critical to the development and

et al., 2019). We provide recommendations for clinical management,

function of the central nervous system. Loss‐of‐function variants in

including surveillance and symptomatic treatment. Annotation and

several genes of the autophagy pathway lead to both neurodevelop-

classification of all disease‐associated variants according to the

mental and neurodegenerative diseases (Ebrahimi‐Fakhari et al., 2016;

current ACMG recommendations are provided (Richards et al.,

Menzies et al., 2017; Teinert et al., 2019).

2015). Using public databases, we estimate carrier frequencies and

In 2012, Oz‐Levi et al. identified the homozygous TECPR2 variant

disease incidence. Based on this curated phenotype and genotype

c.3416del, p.(Leu1139Argfs*75) in five individuals from three Jewish

data set, we propose a framework for reporting and validating

Bukharian families and classified the syndrome as a novel subtype of

TECPR2 variant alleles.

hereditary spastic paraplegia (HSP) (SPG49; MIM# 615000) (Oz‐Levi
et al., 2012). To date, 11 individuals with bi‐allelic TECPR2 variants have
been reported (Covone et al., 2016; Heimer et al., 2016; Oz‐Levi

2 |

MA T ER I A L S A N D M ET H O D S

et al., 2012; Patwari et al., 2020; Zhu et al., 2015). All individuals showed
muscular hypotonia and most had global developmental delay followed

2.1 | Editorial policies and ethical considerations

by intellectual disability. Only a subset of individuals displayed progressive spasticity as a characteristic HSP symptom. An autonomic and

This study adheres to the principles set out in the Declaration of

sensory neuropathy with respiratory, gastrointestinal and cardiovascular

Helsinki. The following Research Ethics Committees approved the

system involvement was present in a subset of individuals and central

study: Ethical Committee of the Medical Faculty, Leipzig University

apnea was found to account for a large part of the morbidity (Heimer

(P1), Institutional Review Board at Boston Children's Hospital

et al., 2016; Patwari et al., 2020).

(IRB‐P00033016; P2, P4, and P5), Ethics Review Board of

Beside two founder variants (c.3416del, p.(Leu1139Argfs*75) in

Technical University of Munich (P3), Institutional Review Board of

the Jewish Bukharian background and c.1319del, p.(Leu440Argfs*19)

King Faisal Specialist Hospital and Research Center (KFSRHC RAC#

in the Jewish Ashkenazi background), likely derived as new variants

2080006 and 2121053; P7, P8, and P13), Institutional Review

under a Clan Genomics hypothesis (Lupski et al., 2011), two other

Board at University College London (P14 and P15, SYNaPS cohort),

truncating and three missense TECPR2 variants have been associated

East of England and South Cambridge Research Ethics Committee

with the disease. Expression analyses in cell lines transfected with the

(REC: 14/EE/1112) for 100,00 Genomes Project Protocol (P16),

p.(Leu1139Argfs*75) variant indicated escape from nonsense‐mediated

Institutional Review Board at Baylor College of Medicine (H‐29697)

RNA‐decay (NMD) but the degradation of the truncated protein

and Comité Etico Cientifico at Facultad de Medicina, and Clinica

(Oz‐Levi et al., 2012). Functional data is largely missing for other de-

Alemana Universidad del Desarrollo (P17). Genetic testing for P6,

scribed variants. This poses challenges for the interpretation of mis-

P9, P10, P11, and P12 was performed in a diagnostic setting. The

sense variants, for which normal expression of an altered protein is

authors received and archived written consent of the legal

expected. All variants have been reported based on the clinical overlap

guardians to publish genetic and clinical data (P1 ‐ P17) as well as

but have yet to be scored through the five‐tier variant classification

photographs, computed tomography (CT) scan, and magnetic

system recommended by the American College of Medical Genetics

resonance imaging (MRI) images (P1, P4, P6, P11, P13, P15,

and Genomics (ACMG) (Richards et al., 2015). The lack of functional

P16, P17).

data and reliable variant classification have prevented an estimation of
carrier frequencies and disease incidence, genotype‐phenotype
correlation analyses and the ability to make a genetic diagnosis in

2.2 | Cohort

novel cases.
Through international collaboration, we assembled a cohort of

All 17 individuals described herein (P1–P17) were recruited through

28 individuals from 24 families of different ethnic backgrounds with

GeneMatcher (Sobreira et al., 2015) or personal communication, from
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different institutions in Germany, Israel, the United States, Saudi Arabia,

details see Supporting Information File S1). All diagnostic TECPR2 var-

the United Arab Emirates, Great Britain, Pakistan, and Chile. Genotypic

iants were subsequently reclassified (Supporting Information File S3

data from P3 and P13 were previously reported without a detailed

sheet

clinical description (P3: reported as CB‐DYS‐125 in Zech et al., 2020;

et al., 2015).

“TECPR2_variants”)

following

ACMG

guidelines

(Richards

P13: reported as 09DG00835 (Shams Anazi et al., 2017)).

2.3

| Clinical spectrum

2.7 | Estimation of carrier frequencies from public
databases

Molecular and clinical data were collected from the referring clinicians

We retrieved all TECPR2 variants from gnomAD (Karczewski et al., 2020)

using a standardized questionnaire. All affected individuals were eval-

and BRAVO (see Web Resources). These were annotated, scored, and

uated by a pediatric neurologist and/or geneticist. Reports of brain MRI

filtered for classification as (likely) pathogenic as described before to

scans were available from 15 individuals. Clinical terms were standar-

calculate carrier frequencies (Hebebrand et al., 2019).

dized using Human Phenotype Ontology (HPO) terminology (Köhler
et al., 2019). Clinical features were grouped into six categories (phenotypical abnormalities of body and face, intellectual and social development, neurological system, respiratory system, gastrointestinal system,

2.8 | Analysis of missense variant spectrum and
modeling of TECPR2 protein structure

and diagnostic procedures). Detailed case descriptions for all included
individuals are provided in Supporting Information Files S1 and S2 (sheet

The distribution of TECPR2 missense variants in the secondary protein

“clinical_table”).

structure was compared to missense variants reported as homozygous in
public population databases and protein regions constrained for missense
variation were analyzed as described (Hebebrand et al., 2019). For

2.4

| Genetic analyses

analysis of the tertiary structure, we used the GalaxyWEB pipeline (Heo
et al., 2013; Ko, Park, Heo, et al., 2012; Ko, Park, & Seok, 2012) to divide

Genomic DNA was extracted using standard methods from periph-

TECPR2 protein sequence into modeling units, predict their structure,

eral blood samples of probands/parents. For P1, P16, and P17 con-

and refine the top model. Protein data bank (PDB) format structures

ventional karyotyping was performed and all individuals, except P4,

(Popp & Neuser, 2020) were then used for visualization with a pipeline

P14, P15, P16, and P17, received a chromosomal microarray. TECPR2

using the Pymol software (Meyer et al., 2016) and missense clustering

variants were identified by gene panel analysis (P13), exome (P14

analysis as described before (Hebebrand et al., 2019). For details, also see

and P15), trio exome (P1 to P6, P10, P17), quad exome (P7 and P8),

Supporting Information Notes S1.

trio genome (P16), or targeted Sanger sequencing (P9, P11, P12). All
herein identified TECPR2 variants have been submitted to ClinVar
(Supporting Information File S3 sheet “TECPR2_variants”).

2.5

| Review of published cases

2.9 | RNA expression analysis for the TECPR2
variant c.2829del, p.(Asn944Thrfs*7) in P1
Messenger RNA (ribonucleic acid) from peripheral blood lymphocytes of P1 and both parents was used to generate complementary

A PubMed search identified five publications (Covone et al., 2016;

DNA (cDNA). Monoallelic expression was analyzed with reverse

Heimer et al., 2016; Oz‐Levi et al., 2012; Patwari et al., 2020; Zhu

transcription polymerase chain reaction (RT‐PCR), and Sanger se-

et al., 2015) describing 11 individuals from nine families diagnosed

quencing and TECPR2 expression were analyzed using quantitative

with TECPR2‐associated disease (searched on 2020‐09‐10). Pheno-

PCR (qPCR) (see details in Supporting Information File S1).

typic features were extracted from published reports using the same
questionnaire applied to novel cases.

3 |
2.6

| Variant annotation and scoring

RES ULTS

3.1 | TECPR2 Variant Spectrum

Variants were standardized to the TECPR2 reference transcript

Genetic analyses, including conventional karyotyping, chromosomal mi-

NM_014844.4 (GRCh37/hg19) using Mutalyzer 2.0.32 (Wildeman

croarray analysis, and multigene panels (except for P13) were un-

et al., 2008) and annotated as described previously (Popp et al., 2017)

remarkable in all novel cases. Seventeen distinct variants in TECPR2,

with up‐to‐date versions of all tools (Cingolani, Patel, et al., 2012;

including nine truncating and eight missense variants, were identified. Of

Cingolani, Platts, et al., 2012; Freeman et al., 2018; Liu et al., 2013) and

these, five truncating and five missense variants have not been reported

scores (Jian et al., 2014; Rentzsch et al., 2019; Xiong et al., 2015) (for

previously (Figure 1a).
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F I G U R E 1 TECPR2 structure with variant distribution and computational scores. (a) Schematic of the TECPR2 protein with WD40 and
TECPR repeat units (WD40: green, TECPR: orange; based on Uniprot O15040) and three modeling units (“N‐terminal”: gray, “central”: white,
“C‐terminal”: purple) identified by GalaxyDom. Disease‐associated variants identified in the cohort are depicted toward the top. The length of
the segments corresponds to each variant's CADD score. Blue dots represent novel identified variants, black dots represent variants reported
in the literature, and green dots represent the founder variants. Gray dots downwards show homozygous variants from gnomAD, the dot size
represents the logarithm of the allele count. In the panel below, a generalized additive model shows the values of CADD PHRED v1.6 for all
possible missense variants in TECPR2 across the linear protein structure. The red horizontal line marks the recommended cut‐off (20). (b)
Homology model of the N‐terminal domain (AA 1–357; gray) generated through the GalaxyTBM pipeline showing the 7‐bladed β‐propeller fold
typical for WD40 repeat. The position of missense variants identified in the individual P3 (Gly239) from our study and “Family E II‐1” (Thr189)
from the literature review are presented as red spheres. Both missense variants affect conserved residues in β‐propeller folds. (c) Lateral
overview of the homology model of the C‐terminal domain (AA 802–1411; blue) showing the two β‐propeller folds in the TECPR repeat unit.
The position of missense variants identified in the individuals P7 and P8 (Asp1000), P6 (Trp1140), P17 (Arg1336), and P3 (Ala1345) from our
study and “Family H I‐1” (Thr903) from the literature review and (Arg1379) from the Spanish water dogs (Supporting Information Notes S1 and
Figure S1) are presented as red spheres. The blue highlighted part of the protein structure in the middle panel is truncated by the most
downstream stop gained variant c.4103G>A, p.(Trp1368*) identified in P14 and contains the amino acid position described as pathogenic in
Spanish water dogs

3.2

| Founder variants

the homozygous allelic state in five individuals from the literature and in
two cases in our cohort. Additionally, the variant was discovered in a

The first reported founder variant (Oz‐Levi et al., 2012) in the Jewish

compound heterozygous state with the Jewish Ashkenazi founder

Bukharian population c.3416del, p.(Leu1139Argfs*75) was identified in

variant in one previously reported individual. Two previously reported
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individuals and four cases in our cohort were homozygous for the

an MAF of 11,974/282,150. In addition, this variant is found homo-

founder variant in the Jewish Ashkenazi population, c.1319del,

zygous in gnomAD (440x).

p.(Leu440Argfs*19). This variant was also found in a compound het-

Analysis of spatial distribution in the linear protein structure in-

erozygous state with a missense variant (Heimer et al., 2016) and an-

dicated that missense variants identified in the bi‐allelic state in in-

other truncating variant (in our cohort). The two founder variants are

dividuals with TECPR2‐associated disease are predominantly located in

located in exons 8 and 16, respectively. GnomAD minor allele fre-

the N‐terminal (amino acid (AA) 1–357) and C‐terminal (AA 802–1411)

quency (MAF) was 37/275,698 for c.1319del, p.(Leu440Argfs*19) and

protein regions. These two regions display a higher restraint for missense

2/247,472 for c.3416del, p.(Leu1139Argfs*75). There were no entries

variation as indicated by higher computational scores and depletion of

for the homozygous occurrence of these variants in the reference po-

homozygous missense variants (Figure 1a and S1).
This finding is further supported by the missense variant de-

pulations with data available.

scribed in Spanish water dogs (Hahn et al., 2015), which is highly
conserved (CADD PHRED score v1.6: 27.2) and located near to the

3.3

| Other truncating variants

c.4033G>C, p.(Ala1345Pro) variant (P3) in the C‐terminal region;
also the amino acid residue affected by this variant is truncated by

Among the cases derived from the literature, one individual carried

the late stop variant c.4103G>A, p.(Trp1368*) identified in P14 (see

compound

Supporting Information Notes S1 and Figure S1).

heterozygous

frameshift

variants

(c.774del,

p.(As-

p259Metfs*44); c.1028_1032del, p.(Lys343Argfs*2)). Novel identified

Our spatial proximity analysis using predicted 3D protein struc-

truncating variants were c.571C>T, p.(Gln191*) (homozygous), c.694dup,

tures failed to identify clusters of missense variants (Table S3) but

p.(Thr232Asnfs*15) (homozygous), c.2829del, p.(Asn944Thrfs*7) (homo-

showed that all affect highly conserved residues in the repeats

zygous), c.3830del, p.(Asn1277Thrfs*43) (compound heterozygous with

forming the N‐terminal 7‐bladed WD40 β‐propeller or the two pre-

Ashkenazi founder variant) and c.4103G>A, p.(Trp1368*) (homozygous).

dicted C‐terminal β‐propeller structures (Figures 1b,c and S2). While

The variants are located in exons 5, 6, 7, 12, 18, and 20. MAF in the

we chose the GalaxyTBM (Ko, Park, & Seok, 2012) model for visua-

heterozygous state was consistent with ultrarare variant alleles (Hansen

lization of the spatial missense distribution in Figure 1, the structural

et al., 2019) and between 0 and 2/251,490 (gnomAD).

similarity of the model predicted de novo by the trRosetta algorithm
(Yang et al., 2020) is remarkable (Figure S2 and Table S2). This convergence of structure prediction algorithms adds confidence to the

3.4 | Expression analysis of the stop codon
containing transcript in P1

derived models and will thus accelerate our understanding of missense variants in genetic disorders lacking experimentally derived
protein structures.

Sanger sequencing of cDNA showed comparable detection of the
normal allele and the allele with the c.2829del, p.(Asn944Thrfs*7)
variant in both carrier parents of individual P1 (Figure 2a). Additionally, RT‐PCR indicated normal expression in individual P1 who

3.6 | Carrier frequency for (likely) pathogenic
TECPR2 variants

is homozygous for the variant (Figure 2b). Comparable expression of
TECPR2 in individual P1, his parents, and in‐house controls was

Our results indicate that at least 1 in 1221 individuals (0.082%) in

confirmed by qPCR (Figure S3).

gnomAD and 1 in 1610 individuals (0.062%) in BRAVO is a carrier
of a (likely) pathogenic variant in TECPR2. In gnomAD, we were able
to estimate the carrier frequency for eight subpopulations, which

3.5

| Missense variants

ranged from 1 in 155 (0.650%; Jewish Ashkenazi) to 1 in 7654
(0.013%; South Asian). Using these frequencies, the expected in-

To date, only three disease‐associated missense variants have been

cidence is at least 1 in 5,961,640 newborns (based on gnomAD) to 1

reported

p.(Leu684Val);

in 10,366,419 newborns (based on BRAVO). Of the analyzed po-

c.2708C>T, p.(Thr903Met)). Novel variants identified include three

pulations (which did not include the Jewish Bukharian population)

homozygous missense variants c.2998G>T, p.(Asp1000Tyr), c.3418T>G,

the highest incidence is expected in the Jewish Ashkenazi popula-

p.(Trp1140Gly) and c.4006C>T, p.(Arg1336Trp) as well as two com-

tion with 1 in 95,864 newborns.

(c.566C>T,

p.(Thr189Ile);

c.2050C>G,

pound heterozygous missense variants c.715G>A, p.(Gly239Arg) and
c.4033G>C, p.(Ala1345Pro). All variants are predicted to be deleterious
by multiple in silico prediction programs except for the previously de-

3.7 | Predicted tertiary TECPR2 protein structure

scribed variant c.2050C>G, p.(Leu684Val) (CADD PHRED v1.6: 5.5;
mean for all reported missense: 24.4). For a complete overview of in

The three different protein modeling algorithms that we have used

silico analyses please refer to Supporting Information File S3. Similar

(Popp & Neuser, 2020) indicated similar results for the overall

results were obtained for the MAF, which is between 0 and

TECPR2 tertiary structure. The N‐terminal domain (AA 1–357)

21/282,852, again except for c.2050C>G, p.(Leu684Val), which showed

containing seven WD‐repeats is predicted to form a 7‐bladed
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F I G U R E 2 Exemplary Sanger sequences, RT‐PCR, and CMA results for P1. (a) Chromatograms of DNA (Sanger sequencing) and RNA
(RT‐PCR on PAXgene stabilized blood) of P1 (down left) and his parents (up left and right). (b) Gel electrophoresis of cDNA‐amplicon. (c) CMA
data for individual P1 showing an unremarkable copy number of chromosome 14 (Log2Ratio top) and SNP allele peak distribution (AllelePeaks
bottom) showing a 6.52 Mb run‐of‐homozygosity (blue) containing TECPR2 (red). cDNA, complementary DNA; CMA, chromosomal
microarray; RT‐PCR, reverse transcription polymerase chain reaction; SNP, single‐nucleotide polymorphism

β‐propeller fold (WD40 domain) with high similarity in all models

perinatal complications. Three individuals were small for gestational

generated. The central region (AA 358–801) could either not be

age. Head circumference at birth was generally within normal limits.

modeled completely due to a lack of template structures or resulted

At last follow‐up, only seven individuals displayed short stature with

in unstructured and highly diverging models. The C‐terminal domain

a height below −2 SD from age‐matched controls, however, all 11

(AA 802–1411), containing the six TECPR‐repeats annotated from

individuals with data available were below average height. Brachy-

UniProt, was predicted to form a double β‐propeller motif in most

cephaly and microcephaly were observed in seven and four in-

models with good structural similarity and five to seven blades per

dividuals, respectively, with three individuals presenting both.

propeller. Overall, this indicates a structured C‐terminal WD40‐

Distinct facial features were seen in 11 individuals though were not

domain

double

uniform. Shared characteristics included a short neck, synophrys and

β‐propeller motif in the C‐terminus, linked by a 444 AA long un-

a triangular‐shaped face, still a recognizable pattern, or facial gestalt,

structured peptide (Figures 1b,c and S2).

was not appreciated. Skeletal abnormalities, including significant

and

TECPR‐repeat

containing

a

structured

lumbar kyphosis, a barrel‐shaped chest, or hyperextension of the
neck were present in five cases.

3.8

| Clinical spectrum

The ages at diagnosis in our cohort ranged between 13 months and
15 years with a mean of 55.6 ± 48.8 (SD) months. All affected individuals

In our cohort of newly diagnosed cases, 11 of 17 individuals were

showed global developmental delay and later intellectual disability (DD/

male. Age at last follow‐up was between 16 months and 15 years

ID) in the mild (n = 1), moderate (n = 7), and severe (n = 8) ranges. P2 had

with a mean of 65.2 ± 43.7 (SD) months. Consanguinity was reported

only mildly delayed gross motor skills at the last investigation, but her

in 7 out of the 15 families. Five families were of Jewish Ashkenazi

young age rendered a detailed assessment difficult. Six individuals with

descent, two families were of Jewish Bukharian descent. Except for

moderate or severe development delay were reported to have beha-

P1, all individuals were born at term without significant pre‐ or

vioral dysregulation with hyperactivity, restlessness, and aggressive
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behaviors. Two received a formal diagnosis of autism spectrum disorder.
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DISCUSS ION

Ten children (age range: 16 months to 8 years) had not started walking at
the time of the last follow‐up and 7 individuals walked independently

We here report a series of 17 individuals with bi‐allelic TECPR2 variants

(mean age: 40.5 ± 36.2 (SD) months). P3 was diagnosed with dystonic/

from eight nonconsanguineous families and nine consanguineous families

dyskinetic cerebral palsy and started walking around the age of 10 years.

and combine the detailed clinical, imaging, and molecular characterization

Speech development was delayed in all children and speech remained

of these individuals with the 11 cases previously reported. Since the

limited to a few words with five individuals remaining completely

variant c.2050C>G, p.(Leu684Val) was classified as likely benign ac-

nonverbal.

cording to ACMG criteria, one previously reported case (Covone

The most common neurological manifestations in our cohort

et al., 2016) was excluded. The proband's different clinical presentation

included axial and appendicular hypotonia (17/17) accompanied by

without developmental delay, autonomic nervous system involvement or

gait ataxia (11/11), hyporeflexia of the lower limbs (13/17), and

abnormal facial shape supports the variant assessment. Additionally, an

dysarthria (6/8). Autonomic dysfunction, for example, temperature

inherited variant of unknown significance in SPG7 was reported as an

instability (3/14) and hyperhidrosis (2/14) were noticed in a subset of

additional genetic finding (Covone et al., 2016). The analysis of the re-

cases (5/15). Four individuals were reported to have impaired pain

maining 27 individuals defines a core set of clinical and molecular fea-

sensation (4/16). Febrile seizures were found in P1 as well as P10;

tures. These consist of global developmental delay and intellectual

P13, P14, and P15 were reported to have medically refractory epi-

disability, axial and appendicular hypotonia, dysarthria, and an abnormal

lepsy and peripheral neuropathy was diagnosed in P6. Hearing im-

gait, often described as an ataxic gait. Peripheral neuropathy was found

pairment (3/13) and visual impairment (5/12) were present in a

in two‐thirds of all individuals in whom a detailed neurological assess-

subset. The constellation of central respiratory dysregulation, dys-

ment was available. Along with this, hyporeflexia was common and signs

phagia, and neuromuscular‐derived respiratory insufficiency was

of autonomic dysfunction were prominent in the majority of cases. The

common, resulting in central nocturnal (8/13) and/or daytime (5/16)

latter included central hypoventilation, impaired temperature, and blood

hypoventilation, dysphagia (9/17), and impaired clearance of secre-

pressure regulation, repeat aspiration events, and evidence of abnormal

tions. This was complicated by recurrent respiratory infections (14/

gastrointestinal motility. These features imply the involvement of both

15), aspiration events (10/15), gastroesophageal reflux disease (9/

the central and peripheral nervous systems and substantiate features of

15), necessitated noninvasive positive pressure ventilation (i.e.,

hereditary sensory and autonomic neuropathy (HSAN).

nocturnal BiPAP) (2/13), and utilization of gastrostomy tubes (6/11)

Whereas spasticity was recognized as a hallmark feature in the

in a subset. Airway malformation, such as laryngeal cleft or lar-

individuals initially reported (Oz‐Levi et al., 2012), the overall pre-

yngomalacia, was identified in a subset (4/17). Five individuals (5/15)

valence of spasticity was limited to a subset in our analysis (24%).

were reported to have chronic and significant constipation.

We recognize that this is a potentially age‐dependent manifesta-

Clinical manifestations of previously reported individuals are sum-

tion since increased tone was mainly reported in older individuals

marized in Supporting Information File S2. One case (Covone et al., 2016)

(P3 at age 15 years; Family B II‐2 at age 20 years). P3 stands out

was excluded from further analysis since the variant c.2050C>G,

because of the presence of dystonia, which was not present in pre-

p.(Leu684Val) was classified as likely benign according to ACMG criteria.

viously published cases and possibly further broadens the spectrum

In summary, manifestations shared by the majority of all 27 individuals

of neurological symptoms. Of note, epilepsy was relatively infrequent

include global development delay and intellectual disability (26/26,

in our cohort and consisted of two individuals who experienced

100%), muscular hypotonia (27/27, 100%), hyporeflexia of the lower

febrile seizures, two previously reported siblings with infrequent

limbs (22/27, 83%), and gait ataxia (19/19, 100%). Peripheral neuropathy,

generalized tonic‐clonic seizures and three individuals with medically

dysarthria, and abnormal facial features were found in 9/12 (75%), 12/14

refractory seizures. Future studies will be necessary to reassess

(86%), and 19/25 (76%) of individuals with sufficient data available

epilepsy as an associated feature. Overall, the wide neurological

(Table 1). Recurrent respiratory infections (23/25, 92%), gastro-

manifestations in individuals with TECPR2‐associated disease along

esophageal reflux in infancy (18/25, 72%), and nocturnal hypoventilation

the age spectrum, point to an involvement of multiple areas of the

(12/17, 71%) affected most individuals.

central nervous system (i.e., cortico‐spinal tracts, cerebral cortex,
brain stem, possibly basal ganglia) as well as the peripheral nervous
system.

3.9

| Brain imaging and EEG

A large part of the morbidity and mortality associated with
TECPR2 results from central hypoventilation requiring therapy with

A review of 16 brains' MRI studies from our cohort (Figures 3

noninvasive positive pressure ventilation and occasionally active

and S4) and a review of reported cases in the literature defined a thin

mechanical ventilatory support. Our findings are supported by a

corpus callosum as a common feature (11/21, 52%). Additional

recently published, detailed analysis of the distinct breathing pattern

findings in a subset of individuals included mild ventriculomegaly

from one affected individual (Patwari et al., 2020).

(often asymmetric colpocephaly), delayed myelination, and diffuse

Based on our clinical experience and the reported disease

cerebral atrophy. EEG (electroencephalogram) was abnormal in four

manifestations, we suggest a framework for routine surveillance as

cases (4/15, 27%), but no specific pattern was reported.

detailed in Table 2. Symptomatic treatment should be tailored to
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F I G U R E 3 MRI and facial features of individuals with TECPR2‐associated disease. (a) T1 axial and sagittal images of P1 at the age of
four years show delayed myelination, mild ventriculomegaly, and periventricular gliosis. T1 axial and sagittal images of P4 at the age of one year
show mild thinning of the posterior corpus callosum and/or mildly hypoplastic corpus callosum with mild lateral ventriculomegaly. T1 axial and
sagittal images of P11 at the age of 2 years show thin corpus callosum, dysmorphic ventricles, and mild cerebral and cerebellar atrophy.
T1 axial and sagittal images of P13 at the age of 8 years show thinning of the corpus callosum and cerebellar vermis mild atrophy. T1 axial and
sagittal images of P16 at the age of 2 years show dysmorphic ventricles and a reduction in white matter volume. T1 axial and sagittal images of
P15 at the age of 3 years show rounded posterior horns of the bilateral lateral ventricles, cerebral, and mild cerebellar atrophy. (b) Facial
images of P1 (5 years 4 months), P4 (4 years front, 7 years lateral), P11 (4 years front, 3 years lateral), P13 (8 years), P16 (5 years), and P17
(10 years 11 months). Individuals with both facial and MRI are ordered vertically in (a) and (b); the dotted line indicates that for P15 only
MRI images are shown while for P17 only facial images are shown. MRI, magnetic resonance imaging

each individual case and aims at preserving function and preventing

(Heimer et al., 2016; Oz‐Levi et al., 2012), who all lost the ability

long‐term morbidity and mortality. Early developmental support

to walk.

should be maximized to harness the developmental potential.

Due to largely nonspecific initial clinical features, individuals

Overall, our cross‐sectional analysis suggests that there is evi-

with TECPR2‐associated disease may initially receive a diagnosis of

dence of disease progression from a predominantly neurodevelop-

cerebral palsy. In addition to an often unremarkable perinatal his-

mental disorder with global developmental delay and hypotonia in

tory, clinical features that help distinguish TECPR2‐disease from

early childhood to progressive disease with corticospinal and corti-

cerebral palsy include the findings of central apnea/hypoventilation,

cobulbar dysfunction later in life. We know from personal commu-

autonomic instability, hyporeflexia as well as other signs of periph-

nications about the disease course of previously reported patients

eral neuropathy. Brain MRI in TECPR2‐associated disease shows a

HP:0000505
HP:0000365

Visual impairment
Hearing impairment

HP:0001273
HP:0001939

Abnormality of metabolism/homeostasis

HP:0002015

Dysphagia
Abnormal corpus callosum morphology

HP:0002020

Gastroesophageal reflux at infancy

HP:0007110

HP:0030972

Abnormal systemic blood pressure

Central hypoventilation

HP:0002270

Abnormality of the autonomic nervous system

HP:0002877

HP:0007328

Impaired pain sensation

Nocturnal hypoventilation

HP:0009830

Peripheral neuropathy

HP:0002835

HP:0001260

Dysarthria

Aspiration

HP:0002066

Gait ataxia

HP:0002205

HP:0002600

Hyporeflexia of lower limbs

Recurrent respiratory infections

HP:0001252

HP:0011344; HP:0010864

Severe
Muscular hypotonia

HP:0011343; HP:0002342

Moderate

62

53

53

60

31

62

67

93

24

44

0

33

25

25

75

100

76

100

50

44

100

43

25

47

29

44
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(8/13)

(8/15)

(9/17)

(9/15)

(5/16)
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(10/15)

(14/15)

(4/17)

(7/16)

(0/13)
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(11/11)
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(17/17)

(8/16)

(7/16)

(16/16)

(6/14)

(4/16)

(7/15)

(5/17)

(7/16)

(11/16)

Novel cases (%)

25

50

11

90

100

100

50

90

100

75

88

100

100

100

100

100

90

100

86

14

100

100

56
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100
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(1/4)

(3/6)

(1/9)
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(4/4)

(4/8)

(9/10)

(2/2)
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(6/6)

(8/8)
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(6/7)

(1/7)

(10/10)

(4/4)

(5/9)

(6/8)

(2/2)

(7/9)

(8/9)

Literature cases (%)

(22/27)
(19/19)
(12/14)
(9/12)

81
100
86
75

53

52

(9/17)

(11/21)

(10/26)

(18/25)

72
38

(14/25)

(12/17)

71
56

(14/23)

(23/25)

92
61

(6/19)

(10/20)

(7/21)

(15/25)

32

50
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60

(8/20)

(27/27)

100
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(14/23)
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36

57

37

56
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Note: Phenotypes observed >70 % of all cases are presented in bold.

Diagnostic procedures

GI system

Respiratory system

Neurological system

HP:0001263; HP:0001249

HP:0000248

Brachycephaly

Global developmental delay; Intellectual disability

HP:0000252

Microcephaly

HP:0000708

HP:0011842

Abnormality of skeletal morphology

Behavioral abnormalities

HP:0004322

Short stature

Intellectual and social development

HP:0001999

Abnormal facial shape

Phenotypical abnormalities of body and face

HPO

Phenotype

Clinical manifestations of TECPR2‐associated disease

Group

TABLE 1
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Every 6 months
• Neurological examination, including a
developmental assessment
• Evaluation by a pulmonologist
• Evaluation by a gastroenterologist and
consultation with a dietician
• Consider orthopedic evaluation
• Consider venous blood gases
• Consider BERA test if there is clinical
concern for hearing impairment

NEUSER

T A B L E 2 Recommendations for
surveillance and symptomatic treatment

Every 12 months
•
•
•
•
•
•
•
•
•

•

ET AL.

Polysomnography study
Consider chest X‐ray
Consider sputum culture
Consider spine X‐ray
Consider swallow study (unless fed by
gastrostomy)
Consider echocardiography for signs of
pulmonary hypertension
Consider blood pressure monitoring
Consider arterial blood gases
Fasting glucose, electrolytes, and liver
function tests (also during intercurrent
illnesses)
Consider ENT evaluation if snoring or
consistent tonsillar enlargement

Supportive therapy—recommendations
Routine treatments by a physiotherapist, occupational therapist, and speech therapist
Routine chest physiotherapy and mechanical insufflator‐exsufflator device
Consider antacids, H2 blockers or PPI if GERD present
Consider gastrostomy tube and fundoplication if severe GERD/aspiration present
Consider adenoidectomy/tonsillectomy if obstructive sleep apnea present
Consider continuous nighttime pulse oximetry depending on sleep study results
Consider nighttime noninvasive ventilation depending on sleep study results
Use sedatives with caution given reports of prolonged effects in this patient population

thinning of the posterior parts of the corpus callosum in about half of
individuals. This finding can help guide diagnostic testing.
A diagnosis is achieved through molecular testing. With the identi-

In contrast, all disease‐associated missense variants in this cohort affect conserved residues in repeats forming the blades of β‐
propeller structures at the C‐terminal and the N‐terminal ends of the

fication of novel truncating and missense variants, we confirm and

protein (Figure 1). As we could not identify clustering in the tertiary

broaden the spectrum of disease‐associated variants in TECPR2‐

structure, misfolding and subsequent degradation could cause loss of

associated hereditary sensory and autonomic neuropathy with in-

the protein carrying these missense substitutions. All five individuals

tellectual disability. All individuals in the cohort with distinct ethnic ori-

from our cohort harboring missense variants showed moderate to

gins carried the respective founder variant. This observation affirms the

severe DD/ID and are as severely affected as individuals with trun-

expected genotypic trait in the Jewish Ashkenazi and Jewish Bukharian

cating variants. Therefore, our data do not indicate milder clinical

populations. However, the identification of other truncating variants

manifestations in carriers of missense variants. This clinical ob-

provides evidence for the occurrence of TECPR2‐associated disease in

servation further supports a similar pathomechanism, for example,

other ethnic groups. For all families with homozygous variants other than

degradation of truncated or misfolded proteins, for both truncating

the founder variants, consanguinity of the parents was reported. This is

and missense variants. However, due to the currently limited

exemplified for P1 where the run‐of‐homozygosity on chromosome 14

knowledge about TECPR2 function and lack of well‐established and

was not described in the CMA report because it was below the 10 Mb

readily available functional tests, in most cases, missense variants

(mega base) filtering cutoff (Figure 2c). Similar results were reported for

cannot be classified as (likely) pathogenic according to ACMG

P2 and P16 (Supporting Information File S1).

guidelines. Based on our computational analyses, we propose to

Our analysis did not show clustering or specific distribution

consider the following criteria for the interpretation of TECPR2

pattern of the truncating variants. RNA analysis of the novel fra-

missense variants: (1) variant position in the functional domains

meshift variant c.2829del, p.(Asn944Thrfs*7), identified in P1, in-

identified

dicated escape from nonsense‐mediated decay. This argues against

(PM1_Supporting; Figures 1a, S1, and S2), (2) deleterious effect

NMD and is in line with previous results in cell lines showing no

predicted by in silico CADD score with cutoff >20 (PP3; Figure 1a),

effect on mRNA levels for the Jewish Bukharian variant c.3416del,

(3) the patient's phenotype matches the core features as well as

p.(Leu1139Argfs*75) (Oz‐Levi et al., 2012), but instead the resulting

TECPR2‐specific symptoms of the HSAN‐spectrum (Table 1) and

truncated protein being targeted for proteasome‐mediated de-

exome‐wide analyses do not reveal other clinically relevant findings

gradation after translation.

(PP4), and (4) cosegregation of the identified variants with multiple

through

our

conservation

and

modeling

analyses
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affected family members (PP1). In this context, it should be noted

confirm the intended effect by our in silico modeling approach.

that large deletions spanning the whole TECPR2‐gene, in the homo-

Future prospective longitudinal studies are required to better define

zygous state or in trans with another pathogenic variant, would re-

the natural history and patterns of disease progression. Our present

duce the gene dosage and be consequently classified as pathogenic.

study provides a framework for assessing disease manifestations.

This also applies to intragenic duplications disrupting the TECPR2

Close follow‐up and surveillance for neurological and non‐

reading frame (cf. Supporting Information File S2 sheet “allClinVar”).

neurological manifestations are recommended.

However, large duplications encompassing all of TECPR2 are not
expected to disrupt the reading frame and should be evaluated ac-
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